Search For "post marketing surveillance"
Glenmark concludes post marketing surveillance (PMS) study on Favipiravir
Updated : 4 years, 6 months ago IST
Mumbai (Maharashtra) [India], September 15 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India.
Read More
Glenmark's post-marketing surveillance shows no safety concerns on use of
Updated : 4 years, 6 months ago IST
New Delhi [India], September 15 (ANI): The Glenmark Pharmaceuticals' post-marketing surveillance (PMS) study has shown no safety concerns with the use of Favipiravir (FabiFlu®[?]) in India for COVID-19 infection.
Read More
Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu®
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 9 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India.
Read More
Glenmark commences 1000 patients Post Marketing Surveillance study with CO
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], July 13 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu® to closely monitor the efficacy and safety of the drug in
Read More
Glenmark cuts COVID-19 drug Favipiravir price by 27 pc
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], July 13 (ANI): Glenmark Pharmaceuticals said on Monday it has cut the price of its anti-viral drug Favipiravir under the brand name FabiFlu for treatment of patients with mild to moderate COVID-19 by 27 per cent to Rs 75 per tablet.
Read More